News
Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis
15 June 2015
LAU-7b is safe and well tolerated by adult Cystic Fibrosis (CF) patientsThe pharmacokinetic profile fully achieved the protocol dose selection rationaleStudy...
Read MoreA new orphan disease-focused company
5 December 2014
MSBi Valorisation announces the creation of Laurent Pharmaceuticals, a new biopharmaceutical company specializing in rare diseases.MSBi Valorisation announces the creation of...
Read MoreEVENTS
Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 3-6 2024, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022